Tarveda Therapeutics Inc. has refocused its efforts during the past 18 months on Pentarins, the company’s miniaturized drug conjugates designed to target, penetrate and eradicate solid tumors and is in the process of collecting its first human data for the platform.
With $91.8m in venture capital raised to date, Tarveda President, CEO and Interim Chairman Drew Fromkin explained to Scrip’s Mike...








